Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 12/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.72 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.72 |
| ▸ | HRH1 | P35367 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | ESR1 | P03372 | 1/20 | 0.72 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 1/20 | 0.72 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.72 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.72 |
| ▸ | HRH2 | P25021 | 1/20 | 0.72 |
| ▸ | HTR2A | P28223 | 1/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.72 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.72 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.72 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.72 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desfesoterodine SCHEMBL816124 | 1.00 | CHRM3 (0.72) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Desfesoterodine SCHEMBL580657 | 1.00 | CHRM3 (0.72) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Desfesoterodine SCHEMBL29468683 | 1.00 | CHRM3 (0.72) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Desfesoterodine SCHEMBL28757704 | 0.95 | CHRM3 (0.66) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Desfesoterodine SCHEMBL1808420 | 0.94 | CHRM2 (0.68) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Desfesoterodine SCHEMBL1811715 | 0.94 | CHRM2 (0.68) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Desfesoterodine SCHEMBL1808422 | 0.94 | CHRM2 (0.68) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Desfesoterodine SCHEMBL14696972 | 0.92 | CHRM2 (0.62) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| SCHEMBL27490008 | 0.91 | CHRM3 (0.60) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| SCHEMBL27491771 | 0.91 | CHRM3 (0.60) | CHRM3CHRM2CHRM1CHRM5HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 602 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118510500-A | Methods of treating neurological disorders | 地图之光治疗股份有限公司 | 2024-08-16 | — | — | CN | claimed |
| EP-3104848-B1 | INHALABLE PARTICLE FORMULATIONS COMPRISING AN ANTIMUSCARINIC AGENT | CRYSTEC LTD (GB) | 2020-05-06 | — | — | EP | claimed |
| EP-2867199-B1 | STABLE COMPOSITIONS OF FESOTERODINE | HETERO RESEARCH FOUNDATION (IN) | 2018-04-18 | — | — | EP | claimed |
| EP-2545024-B1 | PROCESS FOR PREPARATION OF 3-(2-HYDROXY-5-SUBSTITUTED PHENYL)-3-PHENYLPROPYLAMINES, INTERMEDIATES FOR MAKING HYDROXYTOLTERODINE AND FESOTERODINE | LEK PHARMACEUTICALS (SI) | 2016-08-03 | — | — | EP | claimed |
| US-9085509-B2 | Process for preparing fesoterodine | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2015-07-21 | — | — | US | claimed |
| US-20150182629-A1 | STABLE COMPOSITIONS OF FESOTERODINE | HETERO RESEARCH FOUNDATION (IN) | 2015-07-02 | — | — | US | claimed |
| EP-2867199-A2 | STABLE COMPOSITIONS OF FESOTERODINE | Hetero Research Foundation (IN) | 2015-05-06 | — | — | EP | claimed |
| US-9012678-B2 | Processes for the preparation of fesoterodine | CADILA HEALTHCARE LIMITED (IN) | 2015-04-21 | — | — | US | claimed |
| EP-2686288-B1 | A PROCESS FOR PREPARING FESOTERODINE | ALEMBIC PHARMACEUTICALS LTD (IN) | 2015-03-25 | — | — | EP | claimed |
| EP-2416761-B1 | DESFESOTERODIN IN THE FORM OF A TARTARIC ACID SALT | RATIOPHARM GMBH (DE) | 2015-02-11 | — | — | EP | claimed |
| US-6517864-B1 | Drug delivery patch | PHARMACIA AB (SE) | 2003-02-11 | — | — | US | claimed |
| US-20030027856-A1 | Tolterodine metabolites | BRIDGE PHARMA, INC. | 2003-02-06 | — | — | US | claimed |
| WO-2003002059-A2 | TOLTERODINE METABOLITES | BRIDGE PHARMA, INC. (US) | 2003-01-09 | — | — | WO | claimed |
| US-20020161054-A1 | Use of tolterodine to treat asthma | PHARMACIA & UPJOHN COMPANY | 2002-10-31 | — | — | US | claimed |
| EP-1230209-A2 | STABLE SALTS OF NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SCHWARZ PHARMA AG (DE) | 2002-08-14 | — | — | EP | claimed |
| WO-2002034245-A2 | USE OF TOLTERODINE TO TREAT ASTHMA | PHARMACIA & UPJOHN COMPANY (US) | 2002-05-02 | — | — | WO | claimed |
| EP-1105111-A1 | TRANSDERMALLY ADMINISTERED TOLTERODINE AS ANTI-MUSCARINIC AGENT FOR THE TREATMENT OF OVERACTIVE BLADDER | Pharmacia AB (SE) | 2001-06-13 | — | — | EP | claimed |
| WO-2001035957-A2 | — | — | 2001-05-25 | — | — | WO | claimed |
| WO-2001035957-A1 | STABLE SALTS OF NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SANOL ARZNEI SCHWARZ GMBH (DE) | 2001-05-25 | — | — | WO | claimed |
| WO-2000012070-A1 | TRANSDERMALLY ADMINISTERED TOLTERODINE AS ANTI-MUSCARINIC AGENT FOR THE TREATMENT OF OVERACTIVE BLADDER | PHARMACIA & UPJOHN AB (SE) | 2000-03-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161054-A1 | Use of tolterodine to treat asthma | THOP1, ADRB2, HRH2 | CHRM3 102/4885CHRM2 225/4885CHRM1 332/4885 |
| US-20150182629-A1 | STABLE COMPOSITIONS OF FESOTERODINE | GCG, FUCA2, PDE3A | CHRM3 414/4885CHRM2 708/4885CHRM1 911/4885 |
| US-20030027856-A1 | Tolterodine metabolites | COMT, ADRB3, THOP1 | CHRM3 62/4885CHRM2 42/4885CHRM1 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.